Dual human epidermal growth factor receptor 2 (HER2) blockade has been preclinically and clinically assessed in HER2-overexpressing metastatic breast cancer (mBC) with encouraging results. The findings suggest that dual HER2 blockade in combination with CT is feasible in pretreated HER2-positive mBC patients.

READ FULL ARTICLE Curated publisher From Mdlinx